
Evolent Health (EVH) Stock Forecast & Price Target
Evolent Health (EVH) Analyst Ratings
Bulls say
Evolent Health Inc. demonstrates a strong growth trajectory supported by a robust pipeline of contracts, with a notable $650 million still pending despite recently securing a $500 million deal. The company's expansion in specialty care management services aligns with increasing demand for value-based care, particularly in oncology and cardiology, where a significant portion of the total addressable market remains untapped. Additionally, recent contract adjustments that incorporate risk corridors and cap-rate adjustments reflect Evolent's proactive approach to adapting to industry trends, ensuring continued revenue growth potential.
Bears say
Evolent Health is facing significant challenges as its revenue composition is expected to shift, with non-enhanced revenues declining from approximately $285 million to $170 million between 2025 and 2026. Anticipated declines in Medicaid and Exchange membership could result in a combined EBITDA reduction of $18 million to $25 million, exacerbating financial pressures on the company. Additionally, the company forecasts a sequential revenue decline of $8 million to $18 million in Q4, which raises further concerns about its ability to maintain profitability in a landscape marked by diminishing high-margin enrollment.
This aggregate rating is based on analysts' research of Evolent Health and is not a guaranteed prediction by Public.com or investment advice.
Evolent Health (EVH) Analyst Forecast & Price Prediction
Start investing in Evolent Health (EVH)
Order type
Buy in
Order amount
Est. shares
0 shares